Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Subjects with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)

Sponsor:

AVEO Pharmaceuticals, Inc.

Sponsor Study ID:

AV-299-23-301

CTO #:

103936

NCT Number:

NCT06064877

Phase:

III

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Lip, Oral Cavity and Pharynx

Study Objectives:

To compare the efficacy by overall survival of ficlatuzumab plus cetuximab vs placebo plus cetuximab in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). To evaluate additional endpoints of efficacy for ficlatuzumab plus cetuximab vs placebo plus cetuximab in participants with R/M HNSCC.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)